Fracture Risk Associated With Dimethyl Fumarate Treatment in Multiple Sclerosis Patients: Population Heterogeneity and Temporal Patterns
DMF use is associated with an increased risk of fracture-related AEs, with demographic variations in susceptibility. This study provides critical insights into the safety profile of DMF in MS management, underscoring the need for vigilance in high-risk populations.
Authors
- Jingkai Di (ORCID: https://orcid.org/0000-0002-2814-9400)
- Dongdong He
- Chuan Xiang (ORCID: https://orcid.org/0000-0002-1121-6443)
- Feida Wang
- Lujia Liu (ORCID: https://orcid.org/0000-0001-6744-5459)
- Ping Jiang
Institutions
- Shanxi Medical University (CN)
- Taiyuan Heavy Industry (China) (CN)
- Second Hospital of Shanxi Medical University (CN)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1111/cns.70612
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00